Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma.

Journal Article

Doxorubicin/cyclophosphamide were evaluated as maintenance drugs for dogs with multicentric lymphosarcoma (n = 28). Median remission time of all dogs was 173 days. Remission duration was shorter, however, in dogs with stage IV/V disease, in dogs with pretreatment hypoalbuminemia, and in dogs that had received glucocorticoids before initiation of chemotherapy (P less than 0.04). Nineteen dogs were evaluable for toxicity. Dose-limiting gastrointestinal toxicosis was observed in three dogs, neutropenia was observed in three dogs, and cardiomyopathy was observed in three dogs. The doxorubicin/cyclophosphamide protocol described in this report is safe and effective in treating canine multicentric lymphosarcoma. Clinical stage, pretreatment steroid therapy, and hypoalbuminemia are prognostic factors for response to this protocol.

Full Text

Duke Authors

Cited Authors

  • Price, GS; Page, RL; Fischer, BM; Levine, JF; Gerig, TM

Published Date

  • September 1, 1991

Published In

Volume / Issue

  • 5 / 5

Start / End Page

  • 259 - 262

PubMed ID

  • 1748977

International Standard Serial Number (ISSN)

  • 0891-6640

Language

  • eng

Conference Location

  • United States